Empirical Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Empirical Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.8M	Buy	7,464 +1,799	+32%	+$394K	0.03%	290
2026 Q1	$1.07M	Buy	5,665 +1,133	+25%	+$198K	0.02%	336
2025 Q4	$770K	Buy	4,532 +2,138	+89%	+$328K	0.01%	385
2025 Q3	$316K	Buy	+2,394	New	+$287K	0.01%	595

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

SOADOR

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Empirical Wealth Management's JAZZ Position: Q2 2026 in Review

Empirical Wealth Management increased its Jazz Pharmaceuticals (JAZZ) stake by 32% in Q2 2026, buying an estimated $394K and bringing the position to 7,464 shares worth $1.8M. The position accounts for 0.03% of the portfolio, ranked #290.

Empirical Wealth Management first reported a position in JAZZ in Q3 2025 and has held it in 4 quarters since. 87 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Empirical Wealth Management held 7,464 shares of Jazz Pharmaceuticals worth $1.8M as of Q2 2026.
Empirical Wealth Management bought 1,799 Jazz Pharmaceuticals shares in Q2 2026, an estimated $394K.
Jazz Pharmaceuticals made up 0.03% of Empirical Wealth Management's portfolio in Q2 2026, its #290 holding.
Empirical Wealth Management first reported a position in Jazz Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
87 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.